Stockwinners Market Radar for August 09, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
SXTP | Hot Stocks19:50 EDT 60 Degrees Pharmaceuticals Inc trading halted, news pending
|
SFM | Hot Stocks18:22 EDT Sprouts Farmers Market director Anderson sells 20,851 common shares - In a regulatory filing, Sprouts Farmers Market director Joel Anderson disclosed the sale of 20,851 common shares of the company on August 9 at a price of $96.1616 per share.
|
CMAX | Hot Stocks18:01 EDT CareMax down 4% at $4.35 after Q2 results
|
LMT | Hot Stocks17:31 EDT Lockheed Martin awarded $220M Navy contract modification - Lockheed Martin was awarded a cost-plus-incentive-fee and cost-plus-fixed-fee, unpriced letter contract modification with a not-to-exceed amount of $220M under contract. This effort will support program management, engineering development, systems integration, long lead material, and special tooling and equipment in support of missile and launching platform production for Conventional Prompt Strike. Work under this contract is expected to be completed on July 31, 2028. FY23 Missile Procurement funds in the amount of $980M; FY24 research, development, test, and evaluation funds in the amount of $96.24M and FY24 research, development, test and evaluation funds in the amount of $9.2M, will be obligated upon award. No funds will expire at the end of this fiscal year. This contract is being awarded to the contractor on a sole source basis under 10 U.S. Code 3204(a)(1) and was previously synopsized on the System for Award Management online portal. Strategic Systems Programs is the contracting activity.
|
LMT | Hot Stocks17:25 EDT Lockheed Martin awarded $611.27M Navy contract modification - Lockheed Martin was awarded a $611.27M modification to a previously awarded cost-plus-fixed-fee, cost-plus-incentive-fee contract. Work is expected to be completed in June 2026. FY24 research, development, test and evaluation funds in the amount of $5.72M; FY24 research, development, test, and evaluation funds in the amount of $5.72M; FMS customer funds in the amount of $1.2M and non-Department of Defense participants funds in the amount of $15.53M, will be obligated at the time of award, none of which will expire at the end of the current fiscal year. Naval Air Systems Command is the contracting activity.
|
BA | Hot Stocks17:22 EDT Boeing awarded $2.56B Air Force contract modification - Boeing has been awarded a $2.56B modification to a previously awarded undefinitized contract action, or UCA, for E-7A Rapid Prototyping. The modification is for the definitization of the UCA. Work will be performed in Tukwila, Washington, and is expected to be completed by August 28, 2029. There are no funds being obligated at the time of award. Total cumulative face value of the contract is $2.56B. Hanscom Air Force Base is the contracting activity.
|
DJT | Hot Stocks16:46 EDT Trump Media provides update on launch of Truth+ streaming platform - The company said, "Subsequent to the second quarter, TMTG launched its TV streaming platform, Truth+, across the entire Truth Social platform-iOS, Android, and the Web. The streaming service relies on TMTG's custom-built CDN, which operates through a newly opened data center as the Company works to bring additional data centers into operation. TMTG's ultra-fast streaming technology is powered through specially designed infrastructure with its own servers, routers, and software stack. Thus, TMTG expects to gain full control over its tech delivery stack for streaming across private network CDN, consistent with the goal of rendering the service uncancellable by Big Tech. The Company further plans to introduce streaming apps integrated with the Truth Social platform that will offer cutting-edge features including an interactive 14-day electronic guide, instant catch-up TV on any show broadcast in the previous 7 days, network DVR, video on demand, subscription video on demand, a marketplace, and more. TMTG also plans to unveil apps that allow users to watch streaming content on in-home TV sets and to introduce new advertising capabilities. TMTG expects to expand its streaming options as the rollout continues, focusing on news, Christian content, and family friendly programming. TMTG anticipates that, as the rollout progresses, it will continue stress and beta testing the streaming technology while collecting input from users-and announce when testing is finished and the rollout is complete."
|
HE | Hot Stocks16:41 EDT Hawaiian Electric reports $1.71B loss from wildfire liabilities legal claims - Hawaiian Electric Industries reported a consolidated net loss for Q2 of $1.30B. The results included a $1.71B, or $1.27B after taxes, loss from the accrual of estimated wildfire liabilities from tort-related legal claims, an $82.2M, or $66.1M after taxes, loss from a goodwill impairment at American Savings Bank and $9.8M, or $7.2M after taxes, of other Maui wildfire-related expenses, net of insurance recoveries and deferrals.
|
HE | Hot Stocks16:31 EDT Hawaiian Electric reports 'going concern' risk - HEI and Hawaiian Electric do not yet have a financing plan in place to address the future payment of the $1.71B Maui windstorm and wildfire settlement accrued in Q2 of 2024. Until a definitive financing plan is developed and is probable of being implemented, HEI and Hawaiian Electric will disclose a "going concern" risk in their financial statements. After definitive financing plans are in place and likely to be implemented, such a going concern risk is expected to be resolved. This risk is the result of estimated payments under the settlement agreement. HEI and Hawaiian Electric are working closely with their financial advisors to develop a financing plan for their settlement contribution, and intend to finance the settlement payments through a mix of debt, common equity, equity-linked securities, or other potential options, although there can be no assurance at this time as to the availability or terms of any such financing.
|
HE | Hot Stocks16:30 EDT Hawaiian Electric agrees to settle claims related to Maui wildfires - "Last week we announced that HEI, Hawaiian Electric and other defendants had entered into an agreement in principle to settle all tort claims related to the Maui wildfires. The settlement would allow all parties to come together on a path forward. Our board and management team are pleased to have reached this agreement in principle on an expedited basis. We are confident that this settlement represents the best outcome for HEI, as it provides a clear line of sight toward resolution of the wildfire-related tort litigation and increased certainty for our company's path ahead. In the coming months, we will be focused on finalizing the agreement and regaining the strength of our enterprise. Since last August, we have been advancing a strategy designed to support a strong, financially healthy enterprise that will empower a thriving future for Hawaii. Consistent with this approach, HEI has been undertaking a comprehensive review of strategic options for ASB, which is what led us to report a non-cash goodwill impairment for the bank last month. We will continue to take prudent and measured actions to ensure our companies are well positioned to serve our customers and community for the long term," said CEO Scott Seu.
|
APAM | Hot Stocks16:20 EDT Artisan Partners reports preliminary AUM of $162.7B as of July 31, 2024 - Artisan Partners Asset Management reported that its preliminary assets under management as of July 31, 2024 totaled $162.7B. Artisan Funds and Artisan Global Funds accounted for $78.3B of total firm AUM, while separate accounts and other AUM accounted for $84.4B.
|
HUMA | Hot Stocks16:12 EDT Humacyte drops 17% as FDA needs more time for ATEV review
|
HUMA | Hot Stocks16:11 EDT Humacyte says FDA will require more time to complete review of ATEV BLA - Humacyte announced that the U.S. Food and Drug Administration will require additional time to complete its review of its Biologic License Application for the acellular tissue engineered vessel in the vascular trauma indication. The ATEV trauma program BLA was submitted to FDA in December 2023, and the FDA granted a Priority Review in February 2024 and assigned a PDUFA date of August 10, 2024. In a phone call from FDA CBER leadership today, the Company was informed that the FDA required additional time to complete its review. "We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review." said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. "FDA leadership noted that Humacyte's ATEV is a first-in-class product, and that Priority Review had been granted, which allows only a six-month review cycle, as compared to the standard ten-month review cycle for most products. During the course of the BLA review, the FDA has conducted inspections of our manufacturing facilities and clinical sites and has actively engaged with us in multiple discussions regarding our BLA filing, including post-marketing and labeling discussions. Based on these interactions, we are confident in the approvability of the ATEV in treating vascular trauma. The FDA leadership expressed an apology for their inability to complete the review by the PDUFA date, and currently we do not yet have a revised action date." ATEV is a first-in-class bioengineered human tissue that is designed to be a universally implantable vascular conduit for use in arterial replacement and repair. While harvesting vein from a trauma patient takes valuable surgical time, ATEV is available off the shelf, and does not require further injuring the patient to obtain the needed vascular repair material. Humacyte's BLA included positive results from the V005 pivotal Phase 2/3 clinical study, as well as real-world evidence from the treatment of wartime injuries in Ukraine under a humanitarian aid program. ATEV was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents. It was utilized by vascular and trauma surgeons in Level 1 Trauma centers throughout the U.S. and Israel to repair severe limb-threatening and life-threatening injuries, and in front-line hospitals in Ukraine to treat war injuries. In both the civilian and military clinical studies, ATEV was observed to have high rates of patency, or blood flow, and low rates of amputation and infection.
|
SYM | Hot Stocks16:03 EDT Symbotic acquires Veo Robotics in $8.7M transaction - Symbotic announced it has acquired substantially all of the assets of Veo Robotics, an innovator in intelligent safeguarding for industrial robots. Assets purchased under this agreement include the FreeMove(R) 3D depth-sensing computer vision system for industrial workcells and all related intellectual property. By integrating FreeMove into its robotic warehouse automation system, Symbotic expects to increase productivity with more dynamic, flexible human-machine collaboration. "The innovative FreeMove vision system allows Symbotic to enhance productivity for customers and provide the highest levels of safety in environments where humans interact with robots," said Rick Cohen, Chairman and Chief Executive Officer of Symbotic. "We are pleased to have the former Veo Robotics team join Symbotic where they will continue this exciting work as they bring their talent, expertise, and cutting-edge technology to our company." The $8.7M transaction closed on July 19, 2024.
|
AACI | Hot Stocks16:00 EDT Armada Acquisition Corp I trading resumes
|
AACI | Hot Stocks15:59 EDT Armada Acquisition Corp I trading halted, volatility trading pause
|
PCRX | Hot Stocks15:50 EDT Pacira down 48% after court finds Exparel '495 patent not valid - Shares of Pacira BioSciences are down $10.66, or 48%, to $11.70 after the company announced that the U.S. District Court for the District of New Jersey has found that the company's U.S. Patent No. 11,033,495 for Exparel is not valid.
|
PCRX | Hot Stocks15:40 EDT Pacira trading resumes
|
FTEL | Hot Stocks15:38 EDT Fitell Corp trading resumes
|
FTEL | Hot Stocks15:33 EDT Fitell Corp trading halted, volatility trading pause
|
PCRX | Hot Stocks15:27 EDT Pacira reports District Court found company's '495 patent not valid - Pacira BioSciences announced that the U.S. District Court for the District of New Jersey has found that the company's U.S. Patent No. 11,033,495, or "the '495 patent," is not valid. "We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents. In light of the Court's decision, we are considering our legal options, which include pursuing an appellate review at the U.S. Court of Appeals for the Federal Court as warranted. We firmly believe we have built a strong portfolio of intellectual property and that the EXPAREL franchise is well protected on multiple levels. Three separate infringement suits are underway, and we have additional patents that are forthcoming," said Frank Lee, Chief Executive Officer of Pacira BioSciences.
|
PCRX | Hot Stocks15:20 EDT Pacira trading halted, volatility trading pause
|
CUBI | Hot Stocks14:30 EDT Customers Bank names Allen Love chief compliance & AML officer - Customers Bank has appointed Allen Love as Chief Compliance and AML Officer. In this role, Love will be responsible for leading the Bank's enterprise-wide compliance program, ensuring it continues to evolve as regulatory expectations increase. Love will immediately begin work on strengthening Bank Secrecy Act and Anti-Money Laundering protocols for the company's digital asset business in support of the Bank's recent agreement with the Federal Reserve Bank of Philadelphia and the Commonwealth of Pennsylvania. "Customers Bank has always been dedicated to the principles of strong risk management, and we have already taken several important steps towards meeting the expectations of our regulators, including the appointment of Allen Love as Chief Compliance and AML Officer," said Joan Cheney, Executive Vice President and Chief Risk Officer of Customers Bank. "Allen joins us from one of the top 10 banks in the country with a long career in compliance and risk management. I am incredibly confident in his ability to strengthen our programs to further protect the Bank and provide enhanced services to our customers, building off of the work we have already completed."
|
BYND | Hot Stocks13:48 EDT Beyond Meat trading resumes
|
BYND | Hot Stocks13:43 EDT Beyond Meat trading halted, volatility trading pause
|
NWN | Hot Stocks13:39 EDT Northwest Natural Gas names Raymond Kaszuba CFO - Northwest Natural Holding said it has hired Raymond Kaszuba to serve as the company's senior vice president and Chief Financial Officer effective August 31. aszuba comes to NW Natural Holdings from AmeriGas, where he served most recently as interim president and prior to that as vice president and CFO.
|
GNS | Hot Stocks13:35 EDT Genius Group LTD trading resumes
|
MVST | Hot Stocks13:32 EDT Microvast exploring strategic alternatives to enhance liquidity - Microvast said it is exploring strategic alternatives to enhance liquidity including the sale of certain U.S. non-core real estate assets. It is also exploring new customer projects in the Americas, including Canada, and "embarking on additional projects in APAC and EMEA that expand our presence in differentiated commercial vehicle markets."
|
STLA | Hot Stocks13:23 EDT Stellantis says Warren plant to move to one-shift operating pattern in assembly - Stellantis issued the following statement: "The Ram 1500 Classic has been a great entry point pickup for Ram and the Tradesman model has well represented the needs of commercial truck customers for years. We introduced the new 2025 Ram 1500 Tradesman with incredible value and content. The upgraded electrical architecture allows new technologies useful to commercial fleets for better tracking and improved safety systems, such as Forward Collision Warning Plus and adaptive cruise control. Additionally, the available Hurricane Straight-Six Turbo engine provides greater fuel efficiency, vital to lowering total cost of ownership. The new platform also offers more electrification opportunities with the Ram REV and Ramcharger variants that otherwise wouldn't have been available, enabling future compliance. With the introduction of the new Ram 1500, production of the Ram 1500 Classic at the Warren (Michigan) Truck Assembly Plant will come to an end later this year. As a result, Stellantis announced today that the plant will move from a two-shift to a one-shift operating pattern in general assembly. Other operations within the plant will remain on two shifts to support Jeep Wagoneer production. All concerned parties will be notified as required by law." Reference Link
|
GNS | Hot Stocks13:16 EDT Genius Group board approves purchase of up to 10M shares by CEO - Genius Group announced that its board has approved the purchase of up to 10M ordinary shares of the company by Founder and CEO Roger James Hamilton. The shares - to be purchased at 105% of the closing price on the prior trading day - will be issued and paid for by a combination of cash and conversion of debt due from the company, and may be executed over one or more tranches as approved by the NYSE. Roger Hamilton, CEO of Genius Group, said: "I founded this company to make a positive impact to humanity through AI powered education. Now that the AI Revolution is fully underway, I believe Genius Group has an extremely bright future as a potential leader in its field. I proposed this additional share purchase to the board to illustrate my ongoing commitment and confidence in Genius Group as its Founder and CEO. I'm grateful that they have approved it, and I look forward to continuing on our growth journey together." The company added: "With regard to the post by Mr. Hamilton on the X platform on August 7, 2024, any commentary regarding potential numbers of students and revenue goals, which had previously been referenced in press releases, is hereby qualified in that the Company confirms that such statements were not intended as and do not constitute financial projections with regard to the Company or its growth."
|
NVA | Hot Stocks13:15 EDT Nova Minerals Ltd trading resumes
|
NVA | Hot Stocks13:10 EDT Nova Minerals Ltd trading halted, volatility trading pause
|
BKR | Hot Stocks13:01 EDT Baker Hughes reports U.S. rig count up 2 to 588 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 588 with oil rigs up 3 to 485, gas rigs down 1 to 97 and miscellaneous rigs unchanged at 6. The U.S. Rig Count is down 66 rigs from last year's count of 654 with oil rigs down 40, gas rigs down 26 and miscellaneous rigs unchanged. The U.S. Offshore Rig Count is down 1 to 19, up 1 year-over-year. The Canada Rig Count is down 2 from last week to 217, with oil rigs down 3 to 147, gas rigs unchanged at 69 and miscellaneous rig up 1. The Canada Rig Count is up 27 from last year's count of 190, with oil rigs up 31, gas rigs down 5 and miscellaneous up 1.
|
BKR | Hot Stocks13:01 EDT Baker Hughes reports U.S. rig count up 2 to 588 rigs
|
RGC | Hot Stocks12:59 EDT Regencell Bioscience Holdings Ltd trading resumes
|
RGC | Hot Stocks12:54 EDT Regencell Bioscience Holdings Ltd trading halted, volatility trading pause
|
SPRY | Hot Stocks12:52 EDT ARS Pharmaceuticals receives FDA approval of neffy - ARS Pharmaceuticals announced that the U.S. Food and Drug Administration approved neffy 2 mg for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. The approval represents the first significant innovation in the delivery of epinephrine in more than 35 years and is the first and only needle-free treatment option for patients and families living with severe allergic reactions. "Until today, patients with severe allergic reactions, including anaphylaxis, only had one treatment option - an often painful and anxiety-inducing needle injection of epinephrine. In some cases, patients would delay or not administer the life-saving treatment at the onset of symptoms, increasing the risk for a severe reaction or negative outcomes requiring additional emergency medical treatment," said Thomas B. Casale, M.D., Professor of Medicine and Pediatrics and Chief of Clinical and Translational Research in the USF Health Morsani College of Medicine's Division of Allergy and Immunology at the University of South Florida in Tampa, Florida. "FDA approval of neffy means that patients with severe allergies finally gain a long-awaited, needle-free, easy-to-carry epinephrine delivery method that has the potential to reduce time to administration, which can lead to better clinical outcomes and improvements in quality of life for patients and their caregivers."
|
GNS | Hot Stocks12:52 EDT Genius Group LTD trading halted, news pending
|
WAVD AIFF | Hot Stocks12:03 EDT WaveDancer announces reverse stock split, changing name to Firefly Neuroscience - WaveDancer announced that it intends to effect a reverse stock split of its common stock at a ratio of one post-split share for every three pre-split shares. The reverse stock split will become effective at 12:01 p.m., New York time, on Monday, August 12, and will begin trading on a split-adjusted basis when the market opens on Tuesday, August 13. The new CUSIP number for the common stock following the reverse stock split will be 317970101. Additionally, in connection with the Agreement and Plan of Merger, dated as of November 15, 2023, as amended, by and between WaveDancer, Firefly Neuroscience, Inc. and FFN Merger Sub, Inc., WaveDancer will change its name to Firefly Neuroscience, Inc. prior to the consummation of the reverse stock split. Upon market-effective date of the reverse stock split on August 13, the company's name will be Firefly Neuroscience, Inc. and the company's common stock will trade under the symbol "AIFF." Pursuant to the company's registration statement on Form S-4, WaveDancer's stockholders granted the company's board the discretion to effect a reverse stock split of all of the outstanding shares of WaveDancer's common stock through an amendment to its Amended and Restated Certificate of Incorporation at a ratio of not less than 1-for-1.5 and not more than 1-for-20, with the exact ratio and timing to be determined by the board.
|
SG | Hot Stocks12:00 EDT Sweetgreen rises 23.0% - Sweetgreen is up 23.0%, or $6.03 to $32.28.
|
DOCS | Hot Stocks12:00 EDT Doximity rises 31.3% - Doximity is up 31.3%, or $8.04 to $33.70.
|
BLND | Hot Stocks12:00 EDT Blend Labs rises 32.7% - Blend Labs is up 32.7%, or 88c to $3.57.
|
FIGS | Hot Stocks12:00 EDT Figs falls -17.5% - Figs is down -17.5%, or -$1.00 to $4.72.
|
FNA | Hot Stocks12:00 EDT Paragon 28 falls -22.9% - Paragon 28 is down -22.9%, or -$1.90 to $6.41.
|
AVD | Hot Stocks12:00 EDT American Vanguard falls -35.5% - American Vanguard is down -35.5%, or -$2.91 to $5.28.
|
TVGN | Hot Stocks11:04 EDT Tevogen says S-1 does not relate to any previously undisclosed dilutive issuance - Tevogen Bio notes that the company filed a Registration Statement on Form S-1 on June 21, which was declared effective by the Securities and Exchange Commission on August 2, to register the issuance of earnout shares and shares underlying outstanding warrants to purchase the company's common stock as well as the resale of shares and warrants by existing securityholders. "Today, Tevogen Bio reaffirms that the registration statement does not relate to any previously undisclosed new issuances of dilutive securities," the company stated. Tevogen CEO Dr. Ryan Saadi stated, "Given the recent volatility across broader stock market indices as well as in Tevogen stock, I want to express management's conviction in the company's strategy and outlook. Our ultimate objective of helping patients and doctors by providing affordable and accessible therapies remains unwavering. Our efficient business model uniquely underscores this objective. I anticipate the company's most recent financing, for up to $50 million, which finalized in July, will allow us to continue to fund existing operations into the future."
|
TSLA | Hot Stocks10:31 EDT Senator Warren sends letter to Tesla board over Musk's 'conflicts of interest' - Senator Elizabeth Warren sent a letter to Robyn Denholm, the chair of Tesla's board, asking for an investigation into Elon Musk's "apparent conflicts of interest.." The letter states in part, "I write to you with ongoing concern that Tesla's Board of Directors appears to be failing to meet its fiduciary duties to Tesla's shareholders by neglecting to address company CEO Elon Musk's apparent conflicts of interest. Mr. Musk has long juggled various enterprises in addition to Tesla, as he leads several private companies, including SpaceX, Neuralink, The Boring Company, and X Corp. However, recent reporting indicates that Mr. Musk may not be adequately addressing his competing priorities. Regardless of his personal pursuits and his vast personal wealth, Mr. Musk has legal responsibilities to Tesla-a publicly traded company-and its shareholders. The Tesla Board must act to ensure that Mr. Musk is meeting all of these responsibilities. In the event that the Board fails to meet this duty, I am requesting additional information to understand whether intervention by the Securities and Exchange Commission or other regulatory agencies may be necessary." Reference Link
|
ACHR | Hot Stocks10:01 EDT Archer Aviation falls -13.9% - Archer Aviation is down -13.9%, or -56c to $3.44.
|
ELF | Hot Stocks10:01 EDT e.l.f. Beauty falls -13.9% - e.l.f. Beauty is down -13.9%, or -$26.11 to $161.84.
|
AVD | Hot Stocks10:00 EDT American Vanguard falls -25.0% - American Vanguard is down -25.0%, or -$2.05 to $6.14.
|
EVH | Hot Stocks10:00 EDT Evolent Health rises 32.8% - Evolent Health is up 32.8%, or $6.86 to $27.73.
|
BLND | Hot Stocks10:00 EDT Blend Labs rises 36.4% - Blend Labs is up 36.4%, or 98c to $3.67.
|
DOCS | Hot Stocks10:00 EDT Doximity rises 37.2% - Doximity is up 37.2%, or $9.55 to $35.21.
|
MMAT | Hot Stocks09:50 EDT Meta Materials trading resumes
|
ACHR | Hot Stocks09:47 EDT Archer Aviation falls -11.4% - Archer Aviation is down -11.4%, or -46c to $3.54.
|
SVV | Hot Stocks09:47 EDT Savers Value Village falls -12.1% - Savers Value Village is down -12.1%, or -$1.17 to $8.51.
|
AVD | Hot Stocks09:47 EDT American Vanguard falls -28.0% - American Vanguard is down -28.0%, or -$2.29 to $5.90.
|
PBI | Hot Stocks09:47 EDT Pitney Bowes rises 28.6% - Pitney Bowes is up 28.6%, or $1.62 to $7.30.
|
DOCS | Hot Stocks09:47 EDT Doximity rises 29.9% - Doximity is up 29.9%, or $7.68 to $33.34.
|
EVH | Hot Stocks09:47 EDT Evolent Health rises 31.0% - Evolent Health is up 31.0%, or $6.46 to $27.33.
|
FIVN | Hot Stocks09:43 EDT Five9 trading resumes
|
PRTA | Hot Stocks09:40 EDT Prothena trading resumes
|
FIVN | Hot Stocks09:38 EDT Five9 trading halted, volatility trading pause
|
LMT | Hot Stocks09:37 EDT Lockheed Martin delivers first fie C-130J Super Hercules tactical airlifters - A new era of tactical airlift capability for New Zealand has officially begun with Lockheed Martin delivering the first of five C-130J Super Hercules tactical airlifters to the New Zealand Ministry of Defence and New Zealand Defence Force during a ceremony at the Lockheed Martin's facility in Marietta, Georgia, on Aug. 8.
|
LTH | Hot Stocks09:36 EDT Life Time Group files patent for The Ultimate Pickleball - Life Time announced it has filed a patent for The Ultimate Pickleball. Designed to address common issues of inconsistent speed, bounce and durability, the new patent-pending ball will be unveiled during an exclusive event featuring tennis legend and a pickleball fan at Life Time's PENN 1 in New York City on August 19.
|
PRTA | Hot Stocks09:30 EDT Prothena trading halted, volatility trading pause
|
ALK | Hot Stocks09:18 EDT Alaska Air renews partnership with Flyways - Alaska Airlines today announced the renewal of its partnership with Air Space Intelligence, creator of Flyways. This renewal reaffirms the airlines commitment to leveraging innovative technology, including artificial intelligence (AI), to optimize operations while driving fuel efficiency benefits in service of the airline's sustainability journey and long-term path to net zero carbon emissions.
|
CAG | Hot Stocks09:17 EDT Conagra Brands acquires FATTY Smoked Meat Sticks - Conagra Brands announced that it has acquired Sweetwood Smoke & Co., maker of FATTY Smoked Meat Sticks. Financial terms were not disclosed.
|
NVNI | Hot Stocks09:17 EDT Nuvini announces Jose Mario Ribeiro Jr. as board advisor - Nvni Group announced the addition of Mr. Jose Mario Ribeiro Jr as a non-voting board adviser to Nuvini's Board of Directors. Throughout his distinguished career, Mr. Ribeiro has founded over 30 companies within the Grupo Check, excelling in technological innovation and financial services. Ribeiro will work closely with the Board of Directors, offering strategic counsel on various initiatives to ensure Nuvini's continued success.
|
FTFT | Hot Stocks09:17 EDT Future FinTech appoints Li as CEO - Future Fintech Group announced that its Board of Directors approved the appointment of Hu Li as Chief Executive Officer, President and a member of the Board of the Company, effective August 5, 2024.
|
SCLX | Hot Stocks09:07 EDT Scilex signs distribution agreement for ZTlido for parts of Africa, Middle East - Scilex announced a Master Distributor Agreement with Devart Middle East Food, as Master Distributor, and CH Trading Group, as Territories Distributor, to expand the distribution of ZTlido into the countries of Morocco, Tunisia, Libya, Jordan, Iraq, and South Africa. The Master Distributor Agreement is an outgrowth Scilex's existing Product Distribution Agreement with CH Trading Group, under which CH Trading Group is continuing the process of expanding commercialization of ZTlido in the Middle East and North/South Africa markets and has the opportunity to distribute across the broader Islamic world and further expand the relationship for other products in Scilex's non-opioid pain portfolio. Under the Master Distributor Agreement, Devart Middle East assumes the responsibility, among other things, of promoting, marketing, selling and distributing ZTlido, and potentially other Scilex products, through a network of business associates, into the above Designated Territories. ZTlido is a lidocaine topical system approved for the relief of neuropathic pain associated with post-herpetic neuralgia.
|
MBUU | Hot Stocks09:04 EDT Malibu Boats introduces 2025 Malibu Wakesetter 25 LSV - Malibu Boats announced the launch of the redesigned Malibu Wakesetter 25 LSV, alongside the all-new Malibu Command Center and a brand new, state-of-the-art boat builder tool for the 2025 model year. The excitement starts with the 25 LSV's totally redesigned hull. Boasting stunning new aesthetics, the new hull is deeper, making space for more ballast and under-seat storage, while allowing passengers to sit deeper in the boat. In combination with the 25 LSV's elegant, classic bow up front, passengers are shielded from spray during windy, choppy conditions, ensuring an overall smoother, more comfortable ride.
|
WBUY | Hot Stocks09:03 EDT Webuy secures $2M debt financing - Webuy Global entered into a definitive agreement for senior convertible debt with an initial principal amount of $2 million, and up to an additional $4 million with an accredited institutional investor upon mutual agreement. The initial conversion price of the Convertible Security is $0.213 per share, or 150% of the VWAP of the Class A ordinary shares on the trading day preceding the Note issuance. The notes bear zero interest with monthly payments to be made in either cash or stock at the Company's option. Additional details regarding the terms of the Convertible Security are available in the Company's Form 6-K, which has been filed with the Securities & Exchange Commission.
|
MMAT | Hot Stocks08:55 EDT Meta Materials trading halted, news pending
|
AQN | Hot Stocks08:49 EDT LS Power agrees to acquire renewable energy business from Algonquin Power - LS Power announced it has reached an agreement with Algonquin Power & Utilities to acquire its renewable energy business. "This represents a significant strategic investment in and expansion of LS Power's renewable energy portfolio," said Paul Segal, CEO of LS Power. "This business complements our existing fleet of more than 19,000 MW of top-performing renewable, energy storage, flexible gas and renewable fuels projects. We believe this platform will play a significant role in meeting the challenges of rising electric demand and advancing the energy transition."
|
ORBT | Hot Stocks08:48 EDT Orbit International terminates contract of SPS president Nabil Radi Abdou - The Company has terminated the employment contract of Nabil Radi Abdou, the President of its subsidiary, Simulator Product Solutions. Mr. Abdou's contract would have expired on December 31, 2024. Abdou's duties and responsibilities, which included overseeing the engineering department of SPS, have been assumed by key members of the SPS management team. In addition, SPS recently hired an individual who holds a BS degree in Electrical Engineering and a PhD degree in Computer Science, who will be assuming the role of Vice President of Engineering at SPS. As part of the acquisition by Orbit in January 2022, Mr. Abdou, through a corporation owned by him, currently owns 19.9% of SPS. His ownership interest, based on a formula in the Operating Agreement signed at that time, is subject to mandatory repurchase by Orbit for $1,300,000 upon termination of Mr. Abdou's employment. This amount is reflected as a liability on Orbit's balance sheet. Mr. Abdou contends he was wrongfully dismissed and has claimed certain amounts he believes are due him under both his Employment Agreement and in connection with the Company's mandatory repurchase obligation under the Operating Agreement. Orbit believes it has abided by the terms of both the Employment Agreement and Operating Agreement and has valid offsets against amounts due to Mr. Abdou because of damages suffered by Orbit as a result of Mr. Abdou's conduct. The parties have commenced discussions in an attempt to avoid litigation.
|
LPTV | Hot Stocks08:37 EDT Loop Media announces NYSE notice of delisting - Loop Media reported that it received notification from NYSE Regulation of the NYSE American that it had suspended trading of the company's common stock and of its determination to commence delisting proceedings of the company's common stock from the exchange pursuant to Section 1003(f)(v) of the NYSE American Company Guide due to the low selling price of the company's common stock. The Company has a right to appeal the determination to the Exchange's Listing Qualifications Panel, although there can be no assurance that any such appeal will be successful.
|
ABVE | Hot Stocks08:32 EDT Above Food to acquire TRG's Specialty Crop Food Ingredient Division for $34M - Above Food Ingredients has entered into a definitive purchase agreement to acquire the Montana-based Specialty Crop Food Ingredient Division of The Redwood Group, for consideration of $34,000,000 plus working capital, subject to final closing adjustments. Upon the terms and subject to the conditions set forth in the purchase agreement, the consideration payable by the Company in exchange for the Assets will consist of $8,100,000 in cash and 5,600,000 newly issued common shares of Above Food, subject to final closing adjustments and customary closing conditions. The Assets supply high-quality grains, pulses, and specialty crops to customers in over 35 countries in high-growth product categories in both the human and pet food markets. Its vertically integrated model spans from the farm to the consumer, encompassing origination, merchandising, processing, and value-added finishing. The Assets achieve structurally higher margins as a result of its value-added approach, differentiating it from commoditized food and ingredient suppliers, in alignment with Above Food's strategy. In the fiscal year ended December 31, 2023, the Assets generated unaudited revenue of $164 million and an average annual adjusted EBITDA for fiscal years 2021, 2022, and 2023 of $5.3 million. Above Food's Seed-to-Fork approach is central to the Company's strategic positioning, enabling it to maintain control over its entire supply chain, ensuring that its standards for quality, sustainability, safety, and traceability are upheld while sustaining its commitment to regenerative agriculture for the long-term health, resilience, and security of the food supply. By integrating owned production and processing facilities, efficient logistics, and direct distribution channels, Above Food drives strong margins and operational efficiencies.
|
AON CG | Hot Stocks08:32 EDT Aon plc appoints Stavridis to board of direcetors - Aon (AON) announced that Admiral James Stavridis has been appointed to its Board of Directors, effective Aug. 15, 2024. Admiral Stavridis is currently Partner and Vice Chair, Global Affairs of Carlye (CG), a global investment firm, a position he has held since 2018
|
MGRX | Hot Stocks08:19 EDT Mangoceuticals completes migration to DEA-approved telemedicine platform - Mangoceuticals, or MangoRx, announced the migration to its newly developed DEA-approved telemedicine operating system. This milestone marks a significant advancement in MangoRx's capabilities, reinforcing its commitment to innovation and superior patient care. The new operating system, authorized by the DEA and integrated with Surescripts, allows MangoRx's third-party doctor network to prescribe and offer controlled substances. This approval not only distinguishes MangoRx in the Direct-to-Consumer telemedicine space but also validates the Company's cutting-edge technology and regulatory compliance. The company anticipates making these products available to patients before the end of Q3.
|
BFH | Hot Stocks08:17 EDT Bread Financial announces partial repurchase of convertible senior notes - Bread Financial Holdings has entered into separate, privately negotiated repurchase agreements with a limited number of holders of its 4.25% Convertible Senior Notes due 2028 to repurchase $237.6 million aggregate principal amount of the Notes for an aggregate cash repurchase price of approximately $350.0 million. The final aggregate cash repurchase price is subject to adjustment as a portion of the repurchase price will be based in part on the daily volume-weighted average price per share of the Company's common stock over an agreed measurement period beginning on, and including, August 9, 2024. The Repurchases are expected to close shortly after completion of the measurement period, which is expected to be before the end of the current fiscal quarter, subject to the satisfaction of customary closing conditions. Following such closings, approximately $78.6 million principal amount of the Notes will remain outstanding, from an initial issued principal balance of $316.25 million.
|
LVO | Hot Stocks08:16 EDT LiveOne announces total memberships surpass 3.9M - Brad Konkol, Head of Slacker Radio, commented, "We are pleased with our continued growth and extremely enthusiastic regarding the strategic vision of Slacker Radio and LiveOne. Our commitment to building strong B2B partnerships and crafting customizable product offerings for a wide range of businesses remains unwavering. We believe in forging unique, mutually beneficial relationships with both businesses and consumers. By focusing on collaborative opportunities and tailored solutions, we are well-positioned to achieve significant new growth through these strategic initiatives."
|
TKLF | Hot Stocks08:16 EDT Yoshitsu enters into $2.75M strategic loan with Best Life Technology - Yoshitsu's Hong Kong subsidiary Tokyo Lifestyle entered into a $2.75M loan agreement on July 10 with a wholly-owned subsidiary of Tasly Healthcare, a pharmaceutical conglomerate based in China, to support TLS's future growth and development. TLS has secured $2.75M in funding from Best Life Technology, a subsidiary of Tasly, with the term of the loan running from July 15, 2024 to July 14, 2025. The loan is guaranteed by Yoshitsu and Shenzhen Qingzhi Liangpin Network Technology, a wholly-owned subsidiary of TLS. Previously on October 18, the company entered into a strategic cooperation agreement with Tasly to cooperate on matters related to investment in research and development and sales of health products globally. The company expects that its collaboration with Tasly will help solidify and grow its presence in the health product sector.
|
TIGO | Hot Stocks08:15 EDT Millicom committee continues to believe Atlas Luxco offer undervalues shares - The company said, "On August 2, 2024, Atlas Luxco S.a r.l. announced it has increased the offer price of its public cash offers from $24.00 to $25.75 per common share and SDR. The independent committee is of the unanimous opinion that the revised offers continue to significantly undervalue Millicom and recommends that shareholders and SDR holders not accept the offers."
|
HURC | Hot Stocks08:14 EDT Hurco Companies collaborates with Kawasaki Robotics in machine-tending solutions - Hurco Companies and Kawasaki Robotics USA, a manufacturer of industrial robotics and automation systems, announced the formation of a strategic collaboration aimed at enhancing innovation and delivering industrial-grade robotic CNC machine solutions to their customers. The collaboration will leverage the strengths of both companies, combining 50+ years of Hurco's CNC machine and controls innovation for short-run manufacturing operations with 50+ years of Kawasaki's industrial robotics expertise, to provide customers with turnkey robotic machine tending solutions. Together, they will focus on expanding the Hurco product line to include robust industrial-grade robotic machine tending solutions that can keep up with customer demand for high-mix, low-volume parts manufacturing without the need to learn how to program a robot.
|
ACST | Hot Stocks08:12 EDT Acasti Pharma sees cash runway into 2Q26 - At June 30, 2024 the Company had cash and cash equivalents of $19.4 million, as compared to $23.0 million, as of March 31, 2024. The Company believes it has sufficient cash to support operations into the second calendar quarter of 2026.
|
KRBP | Hot Stocks08:11 EDT Kiromic BioPharma reports interim results from Deltacel-01 trial - Kiromic BioPharma reported interim results near the completion of Part 1 of its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel, the company's allogeneic, off-the-shelf, Gamma Delta T-cell, or GDT, therapy, in patients with stage 4 metastatic non-small cell lung cancer, or NSCLC, who have failed to respond to standard therapies. Based on data from the five patients evaluated for Progression-Free Survival, or PFS, in the long-term follow-up, Kiromic has registered a PFS ranging from 2 to 8 months, with an average of 4.8 months. No dose limiting toxicities have been reported by the clinical site for patients that have completed the full course of therapy. One patient was withdrawn from the study before completing the full course of therapy due to an adverse event related to a pre-existing co-morbidity and unrelated to Deltacel. Consequently, this subject could not be evaluated for PFS. Additionally, the sixth and last patient in Part 1 of the Deltacel-01 study started treatment on August 6. Kiromic expects to obtain early safety and tolerability outcomes from the last enrolled patient in September and efficacy results in early October. Kiromic is on track to initiate Part 2 of Deltacel-01 in September.
|
MNPR | Hot Stocks08:04 EDT Monopar Therapeutics announces 1-for-5 reverse stock split - Monopar Therapeutics will effect a 1-for-5 reverse stock split of its outstanding shares of common stock. The company expects that the Reverse Stock Split will become effective at 5:00 pm on Monday August 12 and its common stock will begin trading on a split-adjusted basis at the open of trading on August 13 under the new CUSIP number 61023L207. Monopar's common stock will continue to trade on the NASDAQ Capital Market under the symbol "MNPR". The Reverse Stock Split is an effort to regain compliance with Nasdaq's listing rules. As a result of the Reverse Stock Split, each 5 shares of the Company's issued and outstanding common stock will be automatically combined and converted into one issued and outstanding share of common stock, resulting in the number of outstanding shares of Monopar's common stock being reduced from approximately 17.6 million to approximately 3.5 million immediately following the effectiveness of the Reverse Stock Split. The Reverse Stock Split will affect all holders of shares of our common stock uniformly and each stockholder will hold the same percentage of our common stock outstanding immediately following the reverse stock split as that stockholder held immediately prior to the reverse stock split, except for adjustments that may result from the treatment of fractional shares as described below. The Reverse Stock Split will not affect the number of authorized shares of common stock or the par value of the common stock.
|
AQN | Hot Stocks07:59 EDT Algonquin Power to sell renewable energy business to LS Power for up to $2.5B - Algonquin Power & Utilities announced that it has entered into a definitive agreement to sell its renewable energy business to a wholly-owned subsidiary of LS Power for total consideration of up to $2.5 billion. All amounts are shown in United States Dollars.On August 9, 2024, the Company entered into an agreement to sell the renewable energy business to the Buyer for total consideration of up to $2.5 billion excluding debt, consisting of $2.28 billion of cash at closing and up to $220 million of cash pursuant to an earn out agreement relating to certain wind assets. The purchase price represents a compelling value relative to other precedent transactions. The transaction was unanimously approved by the Company's board of directors.
|
LSPD USFD | Hot Stocks07:57 EDT Lightspeed joins US Foods CHECK business tools - Lightspeed Commerce ( LSPD) announced a new collaboration with US Foods Holding Corp. (USFD), one of the largest foodservice distributors in the United States. Through this collaboration, Lightspeed Restaurant technology will be available throughout US Foods' CHECK Business Tools program, available to thousands of restaurants and food service operators across the United States. This dynamic collaboration will empower ambitious entrepreneurs to accelerate growth, provide exceptional customer experiences, and become go-to destinations in their space.
|
ANTX | Hot Stocks07:56 EDT AN2 Therapeutics to terminate Phase 2, Phase 3 parts of EBO-301 trial - Last night, AN2 Therapeutics announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized background regimen, or OBR, in treatment-refractory MAC lung disease. The Phase 2 part of the study met its primary objective of demonstrating the potential validation of a novel patient-reported outcome tool and a higher PRO-based clinical response rate in the epetraborole + OBR arm vs. placebo + OBR. However, sputum culture conversion at Month 6, a key secondary endpoint, was similar between treatment arms. In February, the company voluntarily paused new patient enrollment in the Phase 3 part of the study due to potentially lower-than-expected efficacy observed in blinded aggregate data. Based on the topline data announced, the company will terminate the Phase 2 and Phase 3 parts of the EBO-301 trial. Oral epetraborole 500 mg daily was generally well-tolerated and the study was not terminated due to safety concerns.
|
CURLF | Hot Stocks07:56 EDT Curaleaf to open new medical dispensary in Florida - Curaleaf Holdings announced it will open a new medical dispensary in Florida. Curaleaf Pensacola, located at 2E 9 Mile Rd, Pensacola, FL 32534, will begin welcoming patients on Friday, August 9. The Company's latest expansion in the Sunshine State will increase its retail footprint to 63 retail locations statewide and 149 nationwide.
|
HUGE | Hot Stocks07:36 EDT FSD Pharma provides update on investment in Celly Nutrition - FSD Pharma provides an update on its investment in Celly Nutrition Corp. On August 9, 2024, Celly Nutrition announced the imminent launch of its product, unbuzzd. The company said, "This milestone marks the beginning of a new era in recovery solutions with the introduction of convenient, grab-and-go stick packs. Designed by scientists for use anywhere, unbuzzd offers consumers an innovative approach to helping accelerate alcohol metabolism, restore mental clarity, and prepare for what's next. Today's recovery drinks focus on alleviating the discomfort known as the "hangover." However, unbuzzd aims to reshape this paradigm. unbuzzd helps your body process alcohol faster, restore mental alertness, and improve cognition so you can drink responsibly and drink refreshingly. unbuzzd appeals to a broad target audience of alcohol consumers who want to have a good time, be in control, and still feel great the next day. Driven by science, unbuzzd is a proprietary blend of vitamins, minerals, and herbs designed to help restore mental alertness, improve cognition, and accelerate alcohol metabolism. This dual mode of action supports swift recovery from inebriation and has revolutionized alcohol consumption recovery. Our world-class R&D team has dedicated themselves to creating this on-the-go, alcohol-reducing nutraceutical." Expected to launch in three packs and eighteen packs on Amazon later this month, these compact, slender packs are easy to carry in a pocket or purse. Celly Nutrition plans to add 12oz Ready to Drink cans to the unbuzzd lineup later this year.
|
TENK CTXR | Hot Stocks07:33 EDT TenX Keane addresses trading halt, continues toward combination closing - On August 7, 2024, TenX Keane Acquisition (TENK) was notified by The Nasdaq Stock Market that trading in TenX's securities had been halted for "additional information requested" from the company. The trading halt was imposed following volatility in the trading price and volume of TenX's securities on Wednesday, August 7, 2024. TenX and its advisors have been in contact with representatives of Nasdaq regarding the lifting of the trading halt. While the trading halt is in place, TenX understands that its securities cannot be traded on any other exchange or in the over-the-counter market. On August 8, 2024, Citius Pharmaceuticals (CTXR) announced that the FDA had approved LYMPHIR for the treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. TenX and Citius Pharma are working diligently toward closing and expect it to occur in the near future. The newly combined public company is to be renamed Citius Oncology, Inc. and will continue to trade on the Nasdaq stock exchange under the symbol "CTOR." Pursuant to the business combination agreement, TenX will acquire Citius Pharma's wholly owned subsidiary via a merger, with the newly combined publicly traded company to be named Citius Oncology, Inc. In the transaction, all shares of Citius Pharma's wholly owned subsidiary will be converted into the right to receive common stock of the new public company, Citius Oncology. As a result, upon closing, Citius Pharma will hold approximately 65.6 million shares of common stock of Citius Oncology which will represent approximately 90% of the new public company. As part of the transaction, Citius Pharma will contribute up to $10 million in cash to Citius Oncology to fund transaction expenses and working capital post-closing. An additional 12.75 million existing options will be assumed by Citius Oncology from Citius Pharma's subsidiary.
|
OCUL | Hot Stocks07:31 EDT Ocular Therapeutix reports inducement grants under Nasdaq listing rule - Ocular Therapeutix has agreed to grant inducement awards to four newly hired employees. The awards were made as inducements material to each individual's acceptance of employment with Ocular under Ocular's 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards to the four newly hired employees were granted effective as of August 5, 2024 and consist of non-statutory stock options to purchase up to an aggregate of 132,400 shares of Ocular's common stock at a per share exercise price equal to the closing price of Ocular's common stock on The Nasdaq Global Market on the effective date of grant and restricted stock unit awards representing the right to receive an aggregate of 44,133 shares of Ocular's common stock. Each stock option has a ten-year term and is scheduled to vest over four years, with 25% of the original number of shares vesting on the one-year anniversary of the recipient's employment commencement date and the remainder vesting in equal monthly installments over the three years thereafter, subject to such individual's continued service to Ocular through the applicable vesting dates. Each restricted stock unit award is scheduled to vest over three years, in equal annual installments, beginning on August 5, 2024, and subject to the recipient's continued service to Ocular through the applicable vesting dates. The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular's 2019 Inducement Stock Incentive Plan.
|
PGY | Hot Stocks07:26 EDT Castlelake to purchase $1B in consumer loans through Pagaya network - Pagaya and Castlelake announced an agreement for Castlelake to purchase, subject to certain terms and conditions, an aggregate amount of up to $1B in consumer loans through the Pagaya network. Following satisfaction of the closing conditions, Castlelake will acquire loans on a monthly basis for an initial 12-month term, with the potential for the agreement to be extended for additional loan purchases over time. This transaction expands and diversifies Pagaya's funding capacity, and adds a new, highly strategic funding partner to Pagaya's network of over 120 institutional investors. Funding mechanisms like forward flow represent a step-change in driving capital efficiency, by enabling Pagaya to fund loan originations with minimal use of its own capital.
|
DTIL | Hot Stocks07:24 EDT Precision BioSciences partner gets FDA clearance for Azercabtagene Zapreleucel - Precision BioSciences announced that its partner TG Therapeutics has received FDA clearance for its investigational new drug, or IND, application to investigate Azercabtagene Zapreleucel in human clinical trials for the treatment of progressive forms of multiple sclerosis. Azer-cel is an experimental allogeneic CAR T therapy discovered by Precision BioSciences and licensed to TG Therapeutics for the treatment of autoimmune diseases. TG Therapeutics anticipates commencing a phase 1 clinical trial in 2024.
|
VEV | Hot Stocks07:16 EDT Vicinity Motor receives demand letters from RBC, EDC - Vicinity Motor Corp. has received letters from Royal Bank of Canada and Export Development Canada which demand full payment of the outstanding debt balances under their respective credit facilities. Royal Bank has demanded payment by August 19, 2024 and EDC has demanded immediate payment. RBC indebtedness totals $19,202,242 plus C$45,251 and EDC indebtedness totals $8,625,000 plus interest of $54,231. Additional interest, costs, fees and expenses under the credit facilities of the respective Secured Lenders continues to accrue. In addition, the Secured Lenders have provided Vicinity with Notices of Intention to Enforce Security pursuant to subsection 244(1) of the Bankruptcy and Insolvency Act. The Company will engage in discussions with its creditors to evaluate potential solutions to enable the Company to carry on in some form in the future; however, there can be no assurances it will be able to successfully do so. The Secured Lenders may enforce their security and/or a receiver or receiver manager may be appointed. Vicinity intends to pursue all available options afforded by law to resolve these matters while continuing to support its customer base. As disclosed in the Company's publicly filed interim financial statements for the three months ended March 31, 2024, the credit facilities were set be renewed on a yearly basis, at the discretion of the Secured Lenders, on July 16, 2024. The Company had actively been working with Royal Bank and EDC on securing a renewal, but Royal Bank and EDC have exercised their discretion not to renew the credit facilities. As set out in the interim financial statements, as of March 31, 2024 the Company had drawn $17,225,000 under the credit facilities. Additional details about the credit facilities can be found in Note 5 of the interim financial statements. The Vicinity Board of Directors remains committed to navigating these challenges as it turns a corner during a difficult time in the transition to broader electric vehicle adoption, leveraging the Company's position as a respected Canadian EV and transit bus OEM providing significant public benefit. Today there are more than 1,000 Vicinity transit buses in operation across North America and Vicinity recognizes this responsibility to support and maintain the critical transportation infrastructure that allows North America's families to fulfill their travel responsibilities. The Company maintained $77.8 million in assets as of March 31, 2024, including $23.5 million of Property, Plant and Equipment, $28.2 million of Inventory and $4.3 million of cash & cash equivalents. As stated in the Company's publicly filed Management Discussion & Analysis for the three months ended March 31, 2024, the Company has been impacted by continued supply chain impacts to its production efficiency, lower than anticipated demand for the VMC 1200, higher than anticipated working capital requirements to support production backlog and insufficient support from lenders. The Company intends for trading of the Company's common shares to continue on the NASDAQ and TSX Venture Exchange, subject to compliance with applicable exchange requirements.
|
EM | Hot Stocks07:14 EDT Smart Share receives minimum bid price notice from Nasdaq - Smart Share has received a notification letter from the Listing Qualifications Department of Nasdaq dated August 7 indicating that for the last 34 consecutive business days, the closing bid price of the company's ADSs was below the minimum bid price of $1.00 per share requirement in Nasdaq Listing Rules. The Nasdaq notification letter has no current effect on the listing or trading of the company's ADSs on Nasdaq. The company is provided with a compliance period of 180 calendar days, or until February 3, 2025, to regain compliance under the Nasdaq Listing Rules. In the event the company does not regain compliance by February 3, 2025, subject to the determination by the staff of Nasdaq, the company may be eligible for an additional 180-day compliance period. In this case, the company will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. The Nasdaq notification letter does not affect the company's business operations, and the company will take all reasonable measures to regain compliance within the prescribed grace period.
|
ARAAF | Hot Stocks07:14 EDT Aclara Resources announces updated MRE at Carina Module - Aclara Resources announced an updated mineral resource estimate of the Carina Module, Aclara's ion adsorption clay project located in Goias, Brazil, which reflects an inferred mineral resource of 298 Mt, an increase from the previously reported inferred mineral resource statement of 168Mt on December 12, 2023. Highlights: The inferred mineral resource for the Carina Module is estimated at 298 Mt, which represents a 77% increase compared to the previously reported inferred mineral resource of 168Mt. The estimate of contained amounts of magnetic elements1 increased approximately 69% compared to the amount reported in the 2023 Resource Statement, reflecting an increase in contained heavy rare earths, from 8,240t to 13,470t, and an increase in contained light rare earths, from 49,832t to 84,565t. Rare earth magnetic elements are critical to the production of permanent magnets that are used in electric vehicles and wind turbines. Metallurgical recoveries of rare earths from the Carina Module remain compatible with the technology patented and successfully demonstrated on a pilot scale by Aclara at its pilot plant located in Chile, which is designed to minimize both cost and environmental footprint. The near-surface location of the deposit results in a low strip ratio providing a positive backdrop for low-cost mining operations. Secured two additional mining rights adjacent to its existing mineral rights in the Carina Module through a public bidding process conducted by the Brazilian National Mining Agency. The two new mining rights will enable Aclara to explore new areas in the future and further optimize the design of the Carina Module. Next Steps: Anticipated completion of an updated preliminary economic assessment of the Carina Module in September 2024. Continuation of the Carina Module pre-feasibility study as previously reported in the Company's press release dated May 6, 2024. Completion of a 15,200-meter Phase 2 reverse circulation drill campaign aimed at converting inferred mineral resources to a measured and indicated mineral resources category, which is expected to be completed by Q4 2024. Execution of a metallurgical test campaign during H2 2024 and H1 2025. Sample collections will be obtained through sonic drilling and sent to SGS Lakefield for mineralogical and recovery characterization, to serve as additional inputs for the Carina Module prefeasibility study and to form the basis for a new piloting operation. Installation and operation of a new semi-industrial scale pilot plant in the State of Goias, Brazil during Q2 2025. The piloting operation will be aimed at confirming the processing parameters and final process flowsheet design for the feasibility study, generating a high purity HREE carbonate for separation trials in support of future off-take agreements, and demonstrating to relevant stakeholders the environmental sustainability of the process design.
|
RNA | Hot Stocks07:13 EDT Avidity Biosciences announces AOC 1044 data - Avidity Biosciences announced positive AOC 1044 5 mg/kg data demonstrated unsurpassed delivery of phosphorodiamidate morpholino oligomers concentrations to skeletal muscle, statistically significant increase of 25% of normal in dystrophin production and statistically significant increase of 37% in exon 44 skipping in people living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the Phase 1/2 EXPLORE44 clinical trial. In addition, AOC 1044 5 mg/kg reduced creatine kinase levels to near normal with greater than 80% reduction compared to baseline. AOC 1044 demonstrated favorable safety and tolerability. Avidity also announced delpacibart zotadirsen as the approved international nonproprietary name of AOC 1044, abbreviated as del-zota. In the Phase 1/2 EXPLORE44 study, del-zota demonstrated: Unsurpassed delivery of PMO of 200 nM in skeletal muscle; Statistically significant 37% increase in exon 44 skipping and up to 66% exon 44 skipping; Statistically significant increase of 25% of normal in dystrophin production and restored total dystrophin up to 54% of normal; Reduction in creatine kinase levels to near normal with greater than 80% reduction compared to baseline; Favorable safety and tolerability with most treatment emergent adverse events mild or moderate in participants with DMD44.
|
PRZO | Hot Stocks07:11 EDT ParaZero granted extension to meet Nasdaq's minimum bid price requirement - ParaZero received a letter from Nasdaq notifying the company that it is eligible for an additional 180 calendar day period, or until February 3, 2025, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement. The company was first notified by Nasdaq of its failure to maintain a minimum bid price of $1 per share for 30 consecutive trading days on February 8, 2024, and was given until August 6 to regain compliance. The company did not regain compliance with the minimum $1 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Nasdaq's staff to afford it an additional 180-day compliance period to cure the deficiency. If at any time before February 3, 2025, the bid price of the company's ordinary shares closes at or above $1 per share for a minimum of 10 consecutive trading days, the company will regain compliance with the Nasdaq Listing Rules, and the matter will be closed.
|
DIIBF | Hot Stocks07:11 EDT Dorel Industries CEO says Juvenile segment is 'on track' - "The Dorel Juvenile segment is on track and we still expect our second half results to improve versus the first half. The new product launches thus far this year will drive higher revenues in the back half of the year, with the fourth quarter expected to be the strongest. While there is the risk of a slowing economy and we are facing higher supply chain costs, we believe we have the levers to offset these challenges and are confident that our strategic initiatives and focus on operational efficiency will continue to drive growth and deliver value for our stakeholders," commented Dorel President & CEO, Martin Schwartz. "Despite not seeing an industry improvement, we are cautiously optimistic that we will deliver increased sales for Dorel Home in the second half. This is based on our new product pipeline and the success we are seeing at brick and mortar. With our focus on cost reduction, we anticipate improving gross margins and a much improved second half versus both first half results and last year's comparative quarter. We continue to monitor the macro-environment and will make additional operational improvements and remain committed to delivering quality products and value to our customers," concluded Mr. Schwartz.
|
AKRO | Hot Stocks07:08 EDT Akero Therapeutics sees cash runway into 2H27 - Akero's cash, cash equivalents and short and long-term marketable securities as of June 30, 2024, were $848.3 million. Akero believes that its current cash, cash equivalents, and short- and long-term marketable securities will be sufficient to fund its Phase 3 SYNCHRONY Histology and Real-World studies through readout of their respective primary endpoints and Akero's current operating plan into the second half of 2027.
|
PROK | Hot Stocks07:06 EDT ProKidney sees cash runway into mid-2026 - Cash, cash equivalents and marketable securities as of June 30, 2024, totaled $431.5 million, compared to $363.0 million on December 31, 2023. We expect that our existing cash, cash equivalents and marketable securities held on June 30, 2024, will enable us to fund our operating expenses and capital expenditure requirements into mid-2026.
|
CHT | Hot Stocks07:06 EDT Chunghwa CFO Vincent Yu-Shen Chen to leave role, Audrey Wen-Hsin Hsu to succeed - Chunghwa Telecom announced that its board of directors has approved the appointment of a new senior executive VP and CFO. The current CFO, Vincent Yu-Shen Chen, will return to National Chengchi University after his secondment period ends. Audrey Wen-Hsin Hsu from National Taiwan University will take over the position with the new appointment set to take effective on September 1.
|
ZNTL | Hot Stocks07:04 EDT Zentalis sees cash runway into mid-2026 - As of June 30, 2024, Zentalis had cash, cash equivalents and marketable securities of $426.4 million, which includes $27.8 million representing the June 30, 2024 fair value of Immunome common stock received by the Company as part of its upfront payment for the out-licensing of its ROR1 antibody-drug conjugate product candidate and ADC platform in January 2024. The Company believes that its existing cash, cash equivalents and marketable securities as of June 30, 2024 will be sufficient to fund its operating expenses and capital expenditure requirements into mid-2026.
|
ZNTL | Hot Stocks07:03 EDT Zentalis CMO Diana Hausman steps down - Zentalis is disclosing that effective August 8, 2024, Diana Hausman, M.D., has stepped down and is no longer serving as the Company's Chief Medical Officer. The Company is conducting a search for a new Chief Medical Officer. Dr. Blackwell will serve as the Company's Interim Chief Medical Officer.
|
ZNTL | Hot Stocks07:03 EDT Zentalis discontinuing development of ZN-d5 - Zentalis is disclosing that it is no longer developing the combination of its BCL-2 inhibitor, ZN-d5, with azenosertib, and is discontinuing development of ZN-d5. The combination of ZN-d5 and azenosertib was studied in 27 patients with R/R AML in a Phase 1 study. Thirteen patients were evaluable for efficacy, and the other 14 patients experienced progressive disease prior to efficacy evaluation or withdrew. The combination demonstrated clinical activity in patients who had been previously treated with venetoclax. Of the 6 patients who completed at least two cycles of therapy and underwent a cycle 3, day 1 bone marrow aspirate: 1 achieved a complete remission with incomplete hematologic recovery and became transplant eligible, 2 patients had decreased BM blast counts, 2 had stable BM blasts, and 1 patient had increased BM blasts. The safety profile was manageable and in-line with other combinations in the R/R AML disease setting.
|
ENSV | Hot Stocks06:49 EDT Enservco sells Colorado assets to HP Oilfied Services for $1.695M - Enservco has sold to HP Oilfield Services certain Colorado based assets of Heat Waves Hot Oil Service, LLC, a wholly owned subsidiary of Enservco. Transaction consideration from HP was $1,695,000, including $1,221,625, in cash and a short-term note of $473,375. The Note will be paid ratably over five months from October 1, 2024 to February 1, 2025. The Transaction's net proceeds are targeted for retirement of debt, specifically borrowings under the Company's Utica Facility. The Company also announced that it is nearing completion of the previously announced acquisition of Buckshot Tucking, LLC with closing expected within days. Sale of Colorado frac water heating assets is consistent with strategy of being less reliant on seasonal-focused business; Net proceeds to be used to pay down certain of the Company's debt obligations, specifically its Utica Facility. Following the pay down, the Company expects to restructure the remaining Utica Facility; Divesting the heating business allows Enservco to redirect its resources, both financial and managerial, towards the transportation and logistics market servicing the broad energy sector; Includes the previously announced and pending Buckshot Acquisition, which is expected to be immediately accretive and strategically transform the Company by entering the logistics market via a business with substantial operational and financial visibility; and The Company will continue to provide both frac water heating and hot oil services across the Marcellus/Utica basins, where last year's Rapid Hot acquisition contributed to significantly improved operating results in the region.
|
MRK | Hot Stocks06:47 EDT Merck ro acquire CN201 from Curon Biopharmaceutical for upfront $700M in cash - Merck and Curon Biopharmaceutical announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. Under the terms of the agreement, Merck through a subsidiary will acquire full global rights to CN201 for an upfront payment of $700 million in cash. Curon is also eligible to receive up to $600 million in milestone payments associated with the development and regulatory approval of CN201. CN201 is currently being evaluated in Phase 1 and Phase 1b/2 clinical trials for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma and relapsed or refractory B-cell acute lymphocytic leukemia, respectively. Preliminary data suggest CN201 has activity in patients with relapsed or refractory B-cell hematologic malignancies and is well tolerated, with the potential to induce significant and sustained reductions in B-cell populations. Merck plans to evaluate CN201 as a treatment for B-cell malignancies as well as investigate its potential to provide a novel, scalable option for the treatment of autoimmune diseases. Closing of the proposed transaction is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. The transaction is expected to close in the third quarter of 2024 and be accounted for as an asset acquisition. Merck expects to record a pre-tax charge of approximately $750 million, or approximately $0.28 per share, to be included in non-GAAP results in the quarter that the transaction closes. As a matter of policy, Merck provides updates to its financial outlook once each quarter and will provide an update to its full-year financial outlook when it reports third-quarter 2024 results.
|
GB | Hot Stocks06:25 EDT Global Blue releases monthly tax free shopping business update for July - In Continental Europe, the issued Sales in Store growth rate grew by +12% in July 2024 vs. last year. This growth was led by a +10% increase in the number of shoppers and a +2% average spend per shopper. The deceleration in July's growth rate is largely due to France where, as expected, the pre-Olympic Games preparations and restrictions had a negative impact on activity in Paris. Regarding origin markets, the positive momentum in issued Sales in Store growth is evident across all nationalities. Mainland Chinese Tax Free Spend led with +33% vs. last year, a slight acceleration compared with the +31% progression in Q2. US Tax Free Spend saw a +15% increase, boosted by an increase of +20% in shoppers, while GCC shoppers experienced a +7% growth rate vs. 2023. When examining destination markets, July showed a positive performance across most destinations, with Spain at +25%, Italy at +19%, Germany at +10% and France at -2%. In Asia Pacific, the issued Sales in Store growth rate continues to remain very high, reaching +64% in July 2024, led by a +49% increase in the number of shoppers and a +10% average spend per shopper. The deceleration in July's growth rate is partly due to a stronger basis of comparison in July 2023 vs. Q2'23 and the recent strengthening of the Yen against all major currencies, particularly against the Chinese RMB. Regarding origin markets, the positive momentum in issued Sales in Store growth continued across all nationalities. Mainland Chinese Tax Free Spend led with +97% boosted by an increase of +107% of Mainland Chinese shoppers. In the meantime, North-East Asia Tax Free Spend grew by +76% vs. 2023 and Hong Kong and Taiwan Tax Free Spend experienced a +60% growth rate vs. 2023. When examining destination markets, July showed a positive performance across most destinations, with Japan +103%, South Korea at +44%, and Singapore at -9%.
|
MGA | Hot Stocks06:11 EDT Magna recommends rejection of 'mini-tender' offer - Magna International has received notice of an unsolicited mini-tender offer made by TRC Capital Investment Corporation to purchase up to 2,000,000 Magna Common Shares, or less than 1% of Magna's outstanding Common Shares, at a price of CDN $57.90 per share. Magna cautions shareholders that the mini-tender offer has been made at a price below recent market prices, representing a discount of 4.49% to the closing price of Magna's Common Shares on the Toronto Stock Exchange on July 29, 2024, the last trading day before the mini-tender offer commenced. Although the offering price represents a premium of 7.58% to yesterday's closing price of Magna Common Shares on the TSX of CDN $53.82, the offer is highly conditional. TRC Capital's offer states that it may withdraw its offer if, among other things, the market price of Magna Common Shares falls below CDN $57.58, for reference, the closing price on the TSX for Magna Common Shares on August 8, 2024, was CDN $53.82, which is already below this threshold; additionally, TRC Capital's offer is not fully funded and is conditioned upon receipt of necessary financing on terms it deems reasonable in its sole discretion. Magna does not endorse TRC Capital's unsolicited mini-tender offer, is not affiliated or associated in any way with TRC Capital, and unequivocally recommends shareholders reject the TRC Capital offer.
|
AIRS | Hot Stocks06:10 EDT AirSculpt Technologies CEO Todd Magazine stepping down, interim CEO named - AirSculpt Technologies announced Todd Magazine has stepped down from his role as CEO and as a member of the Board of Directors of the company. Magazine will serve as an advisor to the company through December 31. Dennis Dean, CFO, has assumed the position of interim CEO until a permanent successor is named.
|
LICY | Hot Stocks06:08 EDT Li-Cycle selects Marcum Canada as its new independent auditor - Li-Cycle announced that the Audit Committee of the company's Board of Directors has unanimously approved the selection of Marcum Canada as the Company's independent registered public accounting firm that will serve as its independent auditor and the Board has approved that the appointment of Marcum be put forward for shareholder approval. The company will reconvene its Annual General and Special Meeting of Shareholders on October 15 at 8:30 a.m. Eastern Daylight Time to vote on the appointment of Marcum and the authorization of the Board to fix Marcum's remuneration.
|
KRKR | Hot Stocks06:07 EDT 36Kr Holdings CFO Lin Wei resigns, XIan Li succeeds - 36Kr Holdings announced that Lin Wei has resigned from her roles as the company's CFO and member of the Board of Directors for personal reasons, effective August 9. Xiang Li has been appointed as the company's new CFO and director, effective immediately. Li joined 36Kr in 2016 and currently serves as financial director. He has nearly two decades of experience in finance, serving in various positions at Samsung, CNH Australia, Sony Ericsson, and Smith & Nephew before joining 36Kr.
|
RKLB | Hot Stocks06:06 EDT Rocket Lab completes hot fire test for new rocket engine Archimedes - Rocket Lab announced last night it has successfully hot fired its new rocket engine Archimedes for the first time, reaching a "technical milestone toward first launch of the Company's new medium-lift rocket, Neutron." Rocket Lab said its engineers completed the hot fire test at the company's Engine Test Complex within NASA's Stennis Space Center in Hancock County, Mississippi, in August.
|
DSY | Hot Stocks06:05 EDT Big Tree Cloud receives noncompliance notification from Nasdaq - Big Tree Cloud announced that it has received a written notification from Nasdaq, notifying the company that it is not in compliance with the minimum market value of publicly held shares requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5550(b)(2) requires companies to maintain a minimum MVPHS of $15M and Nasdaq Listing Rule 5810(c)(3)(D) provides that the failure to meet the minimum MVPHS requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the MVPHS of the company for the last 33 consecutive business days, the company did not meet the minimum MVPHS requirement. The notification letter does not impact the company's listing on the Nasdaq Global Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the company is provided 180 calendar days, or until February 1, 2025, to regain compliance with Nasdaq Listing Rule 5550(b)(2). To regain compliance, the company's MVPHS must exceed $15M for a minimum of 10 consecutive business days. In the event the company does not regain compliance by February 1, 2025, the company may be eligible for additional time to regain compliance, or may face delisting.
|
IMOS | Hot Stocks06:02 EDT ChipMOS reports July revenue $63.1M, up 12.4%
|
SSNLF | Hot Stocks05:59 EDT Samsung recalls over 1M stoves that started 250 fires, killed pets - Samsung is recalling about 1.12M slide-in electric ranges after hundreds of reports of them being turned on accidentally, leading to fires that injured dozens and killed at least seven pets, the Consumer Product Safety Commission said in a statement on Thursday. Samsung has received over 300 reports of unintentional activation of the front-mounted knobs by humans or pets since 2013. These ranges have been involved in approximately 250 fires. At least 18 fires caused extensive property damage. Approximately 40 injuries have been reported, eight of which required medical attention, and there have been reports of seven fires involving pet deaths. Reference Link
|
AMZN | Hot Stocks05:49 EDT CMA says opening formal merger inquiry into Amazon's Anthropic investment - The U.K.'s Competition and Markets Authority said Thursday that it is opening a formal merger inquiry into Amazon's Anthropic investment after getting "sufficient information" about the deal. The end of the initial period and the deadline for the CMA to announce its decision whether to refer the merger for a Phase 2 investigation is October 4, the CMA said. Reference Link
|
KITT | Hot Stocks05:21 EDT Nauticus Robotics enters partnership with FAU to test Aquanaut Mark 2 - Nauticus Robotics announced a partnership with Florida Atlantic University, or FAU, for further testing of its flagship underwater vehicle, Aquanaut Mark 2. Nauticus has contracted with FAU to perform Aquanaut Mark 2 vehicle development testing in the protected waters near the university's Institute for Ocean and Systems Engineering Dania Beach facilities as well as in the deeper waters of the Atlantic Ocean. This partnership is expected to result in approximately 90% savings on vehicle development testing. This phase of testing requires both shallow and deeper waters to fully test functionality while maintaining real-time communication via tether for instant feedback. It also provides the opportunity to carry out tetherless missions that simulate operations the Aquanaut vehicle is designed to accomplish. Without this partnership, testing in mid-range water depths would require the use of more expensive ocean-going vessels.
|
ITI | Hot Stocks05:13 EDT Iteris to be acquired by Almaviva in $335M all-cash transaction - Iteris announced that it has entered into a definitive merger agreement to be acquired by Almaviva, a private Italian digital innovation group, in an all-cash transaction valuing Iteris at approximately $335M equity value. Under the terms of the agreement, Iteris shareholders will receive $7.20 in cash for each share of Iteris common stock. The cash purchase price represents a premium of approximately 68% to the company's closing share price on August 8. The transaction was unanimously approved and will be recommended to its shareholders by the Iteris board of directors. The transaction is expected to close in 2024, subject to approval by Iteris shareholders, required regulatory approvals and other customary closing conditions. Almaviva intends to finance the transaction using committed debt financing. The transaction is not subject to a financing condition. Upon completion of the transaction, Iteris will become a privately held company, and its common stock will no longer be traded on Nasdaq.
|
ASX | Hot Stocks05:10 EDT ASE Technology reports July revenue $1.59M, up 1.7% - Reports July ATM revenue $846M, down 2.4%.
|
TOUR | Hot Stocks05:07 EDT Tuniu receives noncompliance notice from Nasdaq - Tuniu announced that it has received written notification from the staff of Nasdaq dated August 6, indicating that for the last 31 consecutive business days, the closing bid price for the company's American depositary shares was below the minimum bid price of $1.00 per share requirement set forth in Nasdaq Listing Rule 5450. The Nasdaq notification letter has no current effect on the listing or trading of the company's securities on Nasdaq.
|